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ABSTRACT 
Background: The Cholinergic Anti-inflammatory Pathway (CAP) is a nerve-mediated circuit 
through which the vagus nerve regulates the activity of the inflammatory immune response. 
Injury, ischemia or infection activate the afferent vagus. In the medulla oblongata. a response 
is subsequently returned via the efferent vagus, referred to as the inflammatory reflex. The 
signal is propagated to the spleen where specialized T-cells (ChAT) synthesize acetylcholine 
that binds to α-7-nicotinic acetylcholine receptors on macrophages leading to a down-
regulation of inflammatory cytokines. CAP is modified with drugs or by vagus nerve 
stimulation (VNS) in animal models of sepsis, rheumatoid arthritis (RA) and inflammatory 
bowel disease (IBD). Clinical VNS pilot studies have demonstrated reduced inflammation 
and improvement in clinical symptoms in RA and IBD. Chronic kidney disease (CKD), 
characterized by autonomic dysfunction (AD), is linked to chronic inflammation and 
associated with excessive morbidity and mortality mainly from cardiovascular disease. 
The aims of this thesis were to study CAP and VNS in dialysis patients, and to investigate if 
renal denervation (RDN), in patients with resistant hypertension, could influence CAP. A 
final objective was to identify the optimal length of ECG for heart rate variability (HRV), a 
noninvasive tool to assess the cardiac autonomic nervous system, and correlates to 
inflammatory markers. 
Methods and subjects: In study I-III we analyzed LPS stimulated cytokine levels ex vivo 
and the effect of GTS-21, a cholinergic analogue. 
Study I. Twenty dialysis patients and 8 healthy controls provided blood samples which were 
analyzed in the LPS-model. ECG was recorded for HRV in some patients and in all controls.  
Study II. Ten patients scheduled for RDN and 4 disease controls (DC) for elective coronary 
angiography (CA) were included. Bloods were drawn and ECG recorded before procedures, 
1 day after, and in RND patients at follow-up after 3 and 6 months.  
Study III. Twelve dialysis patients underwent VNS treatment with a minimally invasive 
oscillating device before dialysis for 4 weeks. Bloods were drawn and ECG was recorded at 
baseline, after 2 and 4 weeks of treatment, and at 8- and 12-weeks follow-up.  
Study IV. The database HeartBEAT contains inflammatory markers and nocturnal ECG 
recordings from 318 subjects at baseline and 301 at follow-up. The data was used to analyze 
correlations between inflammatory markers, HRV indices, and different lengths of ECG 
recording.  
Results and conclusion: In study I we found that the LPS-induced cytokine response was 
stronger in patients, where reduced HRV confirmed autonomic dysfunvtion, than in controls. 
Adding GTS-21 decreased cytokines in both groups, suggesting that dialysis patients also 
have a functional CAP. Study II showed that RDN had a strong effect on inflammatory 
markers 1 day after RDN, which disappeared during follow-up. With VNS in hemodialysis 
patients (study III) trends in cytokine response appeared but did not reach statistical 
significance. There is a negative correlation between inflammatory markers and HRV 
indices, but CRP alone is not a reliable predictor of autonomic dysfunction. ECG recording 
length of 60 minutes secured reliable HRV analysis. Outside of the protocol, in study III, we 
  
found that 3 out of 4 diabetics could reduce insulin doses with 25 % during the study 
suggesting a potential benefit regarding insulin resistance. Furthermore GTS-21 strengthened 
the cytokine response in study III suggesting a potential additional capacity for VNS. Dialysis 
and CKD patients may be suitable for non-invasive VNS with daily or prolonged treatment in 
future trials. It appears as longer ECG recordings may be useful, but HRV as prognostic tool 
for anti-inflammatory interventions require further studies.  
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LIST OF ABBREVIATIONS 
Ach Acetylcholine 
AKD Acute kidney disease 
AKI Acute kidney injury 
Ang II Angiotensin II 
ANS Autonomic nervous system 
APD Automated peritoneal dialysis 
BP Blood Pressure 
BPM Beats per minute 
CA Coronary angiogrphy 
CAA Cholinesterase activity 
CAP Cholinergic anti-inflammatory pathway 
CAPD Continuous ambulatory peritoneal dialysis 
CKD Chronic kidney disease 
CNS Central nervous system 
CPAP Continuous positive airway pressure 
CRP C-reactive protein 
CVD Cardiovaskular disease 
DAMP Damage-associated molecular pattern 
DC Disease control 
DMN Dorsal motor nucleus 
DOCA Deoxycorticosteroneacetate 
DPB Diastolic blood pressure 
ECG Electrocardiogram 
eGFR Estimated glomerular filtration rate 
EHT Essential hypertension 
ELISA Enzyme-linked immunosorbent assay 
EPO Erythropoietin 
ESC European Society of Cardiology 
ESH European Society of Hypertension 
ESRD End stage renal disease 
F French 
FDA Food and Drug Administration 
GFR Glomerular filtration rate 
GTS 21 i.e. DMXB-A: 3,2,4-dimethoxybenzylidene anabaseine 
Hb Hemoglobin 
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HeartBEAT Heart Biomarker Evaluation in Apnea Treatment 
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HIV Human immunodeficiency virus 
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HMGB1 High mobility group B1 
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HRV Heart rate variability 
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KDIGO Kidney Disease: Improving Global Outcomes 
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LPS Lipopolysaccharide 
MNSA Muscle sympathetic nerve activity 
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NE Norepinephrine 
NN Normal RR intervals 
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NSRR National Sleep Research Resource 
o.d. Oral daily 
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P- Plasma 
PAMP Pathogen-associated molecular pattern 
PBS Phosphate buffered saline 
PCI Percutaneous coronary intervention 
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RA Rheumatoid Arthritis 
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RRT Renal replacement therapy 
S- Serum 
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SDNN Standard deviation of NN 
SLE Systemic Lupus Erythematosus 
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SPB Systolic blood pressure 
SRR Swedish Renal Registry 
T2DM Type 2 Diabetes Mellitus 
T1DM Type 1 Diabetes Mellitus 
TBI Thoracic bioimpedance 
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TNF Tumor necrosis factor 
tVNS Transcutaneous vagus nerve stimulation 
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α7nAChR α-7-nicotinic acetylcholine receptor 
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1 INTRODUCTION 
1.1 EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE 
Globally over 850 million people, with a prevalence of about 10.4% in men and 11.8% in 
women, are estimated to have a chronic kidney disease (CKD) (1-3). Diabetes mellitus, 
glomerulonephritis, hereditary kidney disease, and hypertension are the most common 
underlying causes. The prevalence of CKD varies between parts of the world, but the global 
burden of CKD is continuing to increase mainly due to the increasing prevalence of diabetic 
kidney disease and obesity (4, 5). Most people with CKD are over 65 years of age (6, 7). 
Despite a higher prevalence in women, it is men and individuals under 65 years who are more 
likely to progress to end-stage renal disease (ESRD) (8). 
Cardiovascular disease (CVD) is a major comorbid condition in CKD and accounts for the 
increasing mortality globally in the CKD population in addition to infections and 
malignancies (9, 10). CKD is currently the 10th cause of death in high-income countries and 
is projected to become 5th leading cause of death worldwide in 2040 (1, 2, 11). In Sweden, 
nearly 600 000 people have CKD.  
Due to the lack of effective therapies, many patients develop ESRD, a condition treatable 
only with dialysis or kidney transplantation which are expensive treatment options. Globally 
2.5 million require dialysis for their survival and 1.4 million people live with a kidney 
transplant (3). In Sweden there are close to 4000 dialysis patients and over 5000 transplanted 
individuals (12). The yearly mortality in dialysis in most developed countries is still around 
20%, which is similar to many metastatic cancers (13). In dialysis patients over 70 years 
survival is similar to that of pancreas and lung cancer (14). Comorbidities complicating 
treatment and reduced quality of life are not unusual (5). 
1.2 EPIDEMIOLOGY OF HYPERTENSION 
According to the World Health Organization (WHO) about 25 % of the adult population in 
the world suffer from hypertension (15), which would translate to more than 2 million people 
in Sweden (16). By the age of 65 years, 50 % of the population in Sweden are hypertensive 
and close to half of those are believed to be undiagnosed (17). The etiology of approximately 
90% of hypertension is not well defined and is therefore classified as essential hypertension 
(EHT). Hypertension is the most important risk factor for cardiovascular diseases, primarily 
stroke but also heart failure, coronary artery disease, and kidney disease. Risk factors for 
developing EHT are unhealthy diets, physical inactivity, being overweight or obese, or 
tobacco and alcohol use. Non-modifiable risk factors are age and genetic factors (18).  
The prevalence of obesity and overweight in the world has tripled since 1975. Close to 40%  
of adults over 18 year are overweight and 13% are obese. Globally there are more people 
who are obese and overweight than underweight. Furthermore, obesity and overweight are 
linked to more deaths worldwide than underweight (19). The long-term consequences of 
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cardiovascular disease (CVD), type 2 Diabetes Mellitus (T2DM), and certain forms of cancer 
increase morbidity and mortality rate among obese individuals (20, 21). 
Secondary hypertension is defined as elevated blood pressure with co-existing diseases such 
as kidney disease or diabetes mellitus, and accounts for approximately 10% of all 
hypertension. Secondary causes should also be considered in resistant hypertension, early 
onset, or malignant hypertension events as well as primary aldosteronism, 
pheochromocytoma, hyperthyroidism, renal artery stenosis, and renal vascular disease. In 
recent years obstructive sleep apnea (OSA) has been identified as a common cause of 
hypertension (22).  
 
2 BACKGROUND 
2.1 INFLAMMATION 
2.1.1 Acute inflammation 
The word inflammation is from Latin (inflammatio) and means firing or burning. The 
classical signs of acute inflammation are redness (rubor), swelling (tumor), pain (dolor), local 
heat increase (calor), and impaired function (functio laesa). The inflammatory response 
consists of both cellular and humoral components and actions. The acute inflammatory 
response provides protection following tissue injury and infection by restricting damage to 
the local site, recruiting immune cells to eliminate the invading pathogen, and initiating the 
process of wound repair. (23, 24).  
The acute inflammatory reaction is initiated by tissue damage caused by e.g. trauma, heat or 
cold exposure, ischemia-reperfusion, invasion of bacteria, viruses, or other microorganisms. 
Exposure of cell debris in the tissue activates pattern recognition receptors (PRR), for 
example toll like receptors (TLR), on macrophages, that initiate several cascade reactions. 
Local production of bradykinin promotes vasodilatation and permeability that is further 
enhanced by complement factors (C3a and C5a) binding to mast cells that release histamine, 
prostaglandin, and leukotrienes. The two latter also stimulate chemotaxis for neutrophils. 
Endothelial cells produce adhesion molecules that binds to circulating neutrophils which then 
migrate to the damaged area. Neutrophils start phagocytosis and release of inflammatory 
mediators that attracts macrophages into the tissue and circulating monocytes. Macrophages 
produce inflammatory cytokines such as interleukin (IL)-1, IL-6, and TNF (25, 26). These 
cytokines stimulate coagulation and increase vascular permeability. IL-1 and TNF also 
induce increased expression of adhesion molecules on endothelial cells, allowing for 
circulating neutrophils, monocytes, granulocytes, and lymphocytes to interact with the 
endothelium and extravasate into the inflamed tissues. Monocytes are differentiated into 
macrophages in the tissue. Macrophages also produce other proinflammatory mediators e.g. 
growth factors, that affect fibroblasts to produce collagen and stimulate other macrophages 
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and lymphocytes to maintain the release of mediators and thereby inflammation. The 
collagen production by fibroblast results in scar healing (23, 27).  
Acute respiratory distress syndrome (ARDS) and sepsis are two conditions in where there is 
an  inadequate inflammatory response. In ARDS the inflammation is sustained by immune 
cells in the lung tissue and in sepsis proinflammatory cytokines are produced and excreted in 
an excessive amount causing a “cytokine storm” (28, 29)  
2.1.2 Chronic inflammation 
Chronic inflammation is not primarily defined by the duration of the inflammatory condition 
but also by the immune cells present in the tissue such as lymphocytes, macrophages, and 
plasma cells that mature into B-cells. An inflammatory response includes actions of both 
innate immune cells and immune cells that contribute to the acquired or adaptive immune 
response. Thus, the immune cells that maintain chronic inflammation are activated as a part 
of the acute inflammatory response although with some delay. If the inflammatory stimulus is 
not controlled, the inflammation can become chronic and is consequently sustained by the 
immune system (Fig 1) (30, 31).  
Inflammation has during recent decades been increasingly recognized as an important causal 
or contributing factor in many acute and chronic diseases e.g. myocardial infarction, T2DM, 
hypertension, heart failure, CKD, and RA (18, 30-32). 
. 
 
Fig 1. A schematic illustration 
of the possible course of 
inflammation. TLR – Toll like 
receptor, NLR -nucleotide-
binding oligomerization 
domain receptor. TLR and 
NLR are examples of PRR. 
Sundman  (33). Reprinted with 
permission from The American 
Physiological Society 
2.2 THE AUTONOMIC NERVOUS SYSTEM 
2.2.1 Anatomy and function 
The purpose of the autonomic nervous system (ANS) is to secure and maintain a stable 
physiological balance - homeostasis - while the body is constantly affected by external and 
internal factors. The hypothalamus, the limbic system, the medulla etc. are constantly 
processing information from the internal and external milieu. They distribute nerve signals 
that regulate organ and tissue function whose activity is essential but not guided by 
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consciousness. Regulatory signals are also largely influenced by neural reflexes where 
supraspinal involvement is not required (34). 
ANS is divided into the sympathetic nervous system (SNS) and the parasympathetic nervous 
system (PNS). The two systems supply all organs and tissues in the thoracic and abdominal 
cavities; the heart, the lungs, the liver, the kidneys, the spleen, the intestines etc. Exceptions 
from dual innervation are the adrenal marrow, the sweat glands, the blood vessels of the skin, 
and smooth muscles which have only sympathetic innervation (Fig. 2). Sympathetic and 
parasympathetic nerves usually have the opposite effects on target organs and classically, the 
sympathetic nervous system is usually associated with "fight and flight" and the 
parasympathetic nervous system with "rest and digest" (35).
                  
Fig 2. The autonomic nervous system illustrated with the sympathetic and the parasympathetic divisions and 
schematic overview of innervation by the two systems. The sympathetic cell bodies are found in the thoracic and 
upper lumbar part of the spinal cord. The parasympathetic nerves originate from cranial nerves and lower 
lumbar part of the spinal cord. Image from MSD Manual. Reprinted with permission  from Merck & Co., Inc., 
Kenilworth, NJ
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2.2.1.1 Efferent motor nerves 
The ANS cell bodies are in the cranial nerves and spinal cord. The nerve threads, called 
axons, connect to ganglia and create synapses. The postganglionic axon then extends to an 
effector site. In the SNS, the ganglia are close to the spine, while the parasympathetic ganglia 
are located closer to the target organ. The transmitter substance in all preganglionic nerves 
and parasympathetic postganglionic nerves is acetylcholine that, in the synapses of the 
ganglia, binds to a nicotinic receptor and in the postganglionic synapses to a muscarinic 
receptor. In sympathetic postganglionic synapses, adrenaline or norepinephrine (NE) is 
released and bind to receptors in the target organ (36). 
The sympathetic efferent, outgoing motor nerve cell bodies are in the thoracic and upper 
lumbar parts of the spinal cord. The preganglionic axons form a chain of ganglia that runs 
along the spine on both sides, called the sympathetic trunk. The postganglionic axons are 
distributed to the face, heart, lungs, kidneys etc. and mediate a regulating effect (37). 
The parasympathetic preganglionic nerve cell bodies are in the cranial nerves III (Oculomotor 
nerve), VII (Facial nerve), IX (Glossopharyngeal nerve), X (Vagus nerve), and nerve nuclei 
in the medulla oblongata and in the sacral part of the spinal cord. The parasympathetic 
ganglia are located near or in the target organ (36, 38). 
2.2.1.2 Afferent sensory nerves 
Afferent, incoming sensory axons, have cell bodies in sensory ganglia in the spinal cord and 
cranial nerves. Visceral afferent parasympathetic axons in the glossopharyngeal nerve and 
vagal nerve convey information from the heart, vessels, lungs, and gastrointestinal tract to the 
brainstem via the inferior glossopharyngeal ganglion and inferior vagal ganglion (nodose 
ganglion). The afferent sensory nerves are also included in reflexes that control blood 
pressure, respiration, and heart rhythm via pressure-sensitive baroreceptors and hypoxia-
sensitive chemoreceptors in the aorta and carotid artery (34, 36, 38-40).  
2.2.2 Autonomic dysfunction 
Autonomic dysfunction is characterized by an imbalance between sympathetic and 
parasympathetic nerve activity. It is common in conditions such as CVD, congestive heart 
failure, and septicemia and has been associated with adverse outcome (41-43). 
Cardiovascular autonomic dysfunction has been demonstrated not only in diabetes but also in 
early stages of glucose intolerance and metabolic syndrome (44). 
Autoimmune diseases characterized by chronic inflammation such as rheumatoid arthritis 
(RA) and systemic lupus erythematosus are associated with autonomic dysfunction and a 
reduction in vagus nerve activity (45, 46). Autonomic dysfunction is also a common finding 
in patients with CKD and is in hemodialysis patients associated with poor prognosis (47-51).  
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2.3 HEART RATE VARIABILITY 
2.3.1 Definitions  
Heart rate variability (HRV) analysis based on ECG recordings is one of the most common 
method to assess the ANS regulatory activity (52). Traditionally SNS and PNS have been 
described as two opposing structures where SNS provides stress reactions and PNS relaxation 
(52). Other factors that have an impact on HRV are metabolic (diabetes), endocrinal 
(cortisol), and barometric (orthostatic) (53). HRV is significantly influenced by sex, age, 
physical fitness, clinical comorbidities, smoking, and medication (54-57). Alterations in HRV 
can also be noted with changes in resting state, body position, and breathing pattern which 
may reduce the specificity of HRV for monitoring physiological or pathological situations 
(53, 58). A non-invasive ECG for HRV analysis is typically recorded for 1 minute up to 24 
hours or longer and quantifies the amount of the interval changes between heartbeat cycles. 
A common approach is to use shorter recordings, e.g. 20 min divided into 5 minutes epochs. 
This procedure delivers reliable HRV data except for circadian rhythm that requires at least 
24-hour recordings (53).  
The intrinsic heart rate from the sinus node is approximately 95 to 110 beats per minute 
(BPM). However, the parasympathetic (vagal) efferent influence is greater than the 
sympathetic, which results in approximately 60-80 BPM for an adult in a resting supine 
position. There are several ways to quantify HRV which reflect differences in the interval 
between heart beats. Three different categories are used; time domain, frequency domain, and 
non-linear variables (Tab.1). 
 
 
 
 
 
 
 
 
 
Table 1. HRV. 
Time and 
frequency 
domain 
variables, units 
and definitions. 
HRV indices Unit Definition
NN Normal RR-intervals 
SDNN ms Standard deviation of all normal  intervals 
SDANN ms
Standard deviation of the average NN intervals in 5 minutes 
segments ECG
RMSSD ms
Root mean square successive difference, the square root of the 
mean of the squared differences between adjacent NN.
pNN50 %
Percent of differences between adjacent NN greater than 50 
ms
NN50 ms Number of adjacent NN greater than 50 ms.
Total power ms
2
The power (variance) in the heart period power spectrum up to 
0.4 Hz.
Ultra low 
Frequency 
(ULF) power
ms
2
The power (variance) in the heart period power spectrum up to 
0.0033 Hz.
Very low 
frequency 
(VLF) power
ms
2
The power (variance) in the heart period power spectrum from 
0.0033 to 0.04 Hz.
Low Frequency 
(LF) power
ms
2
The power (variance) in the heart period power spectrum from 
0.04 to 0.15 Hz.
High Frequency 
(HF) power
ms
2
The power (variance) in the heart period power spectrum up 
from 0.15 to 0.4 Hz.
LF/HF Ratio low frequency to high frequency.
T
im
e 
d
o
m
ai
n
F
re
q
u
en
cy
 d
o
m
ai
n
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Standards for measurement, interpretation, and normal values for HRV time- and frequency 
domain in short-term (5 min) and long-term (24 hrs.) ECG recordings, were established in 
1996 by the Task Force set up by the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology (59). In this thesis, time and frequency 
domain variables will be used plus “non-linear” variables SD1 and SD2 derived from a 
Poincaré plot. SD 1 is an index of short-term HRV and equals RMSSD and SD2 is an index 
of long-term HRV and equals SDNN (60).  
2.3.2 Heart rate variability and inflammation 
The heart rate and cardiac output are influenced by the motor vagus nerve. Therefore, HRV, 
which is known as a reliable indicator of cardiac vagal activity, might also be related to 
degree of inflammation. An association between HRV and pro-inflammatory markers such as 
C-reactive protein (CRP), TNF, and interleukin (IL)-6 has been reported in several studies 
(61, 62). This is consistent with the role of the vagus nerve in the cholinergic anti-
inflammatory pathway (CAP) (63). Reduced HRV is associated with adverse outcomes in 
hypertension, systemic inflammation, depression, CKD, and is also associated with an 
increased risk of sudden death (41, 64-67). 
2.4 THE KIDNEYS 
2.4.1 Anatomy and physiology 
The main function of the kidneys is to produce urine and thereby regulate fluid balance by 
tightly controlling electrolytes and removing waste products from the circulation. In each 
kidney there is about 1 million nephrons, which is the functional unit, where blood from the 
renal arterial circulation is filtered across the capillary walls (Fig. 3). The filtrate, that consists 
of approximately 180 Liters per day, is subsequently transported and reabsorbed in the 
tubules and collecting ducts. The final product urine is typically between 1.5-2 Liters per day 
(68).  
The kidneys also regulate blood pressure by several mechanisms which includes the Renin 
Angiotensin Aldosterone System (RAAS) and ANS activity. In the juxtaglomerular 
apparatus, in the glomerulus, there are specialized cells that register sodium concentration in 
the tubules and the volume of blood flow in the efferent arteriole. Blood volume depletion 
induces secretion of renin that results in vasoconstriction in the afferent arteriole and 
increases in sodium reabsorption via both Angiotensin II and Aldosterone systems. (68).  
The kidneys secrete the hormone erythropoietin (EPO) that stimulates the bone marrow to 
produce red blood cells. Furthermore, the kidneys are essential for activation of vitamin D 
from its 25-hydroxyvitamin form to 1,25-dihydroxycholecalciferol, which is biologically 
active and crucial for calcium homeostasis and bone metabolism (69, 70). 
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Fig. 3 The kidney with the nephron and enlarged nephron with anatomical structures. Image by CNX OpenStax, 
Wikimedia.org  
2.4.2 Innervation of the kidneys 
Efferent sympathetic nerves are widely distributed in the kidneys with the highest 
concentration in the arterioles but are also present in the tubular epithelium. Increased 
sympathetic activity stimulates renin release, decreases blood flow, and influences the tubular 
epithelium to reduce sodium excretion (71). Sensory afferent sympathetic nerves are mainly 
concentrated to the pelvis as free nerve endings and are sensitive for pressure, i.e. urine 
volume (72, 73). The renal artery is mainly innervated by sympathetic efferent nerves and 
approximately 80% of them are found in the proximal and middle part, although efferent 
nerve endings in the distal part are located closer to the arterial lumen. Afferent sensory 
nerves are considerably fewer but equally distributed in all parts of the renal artery (74). 
2.4.3 Kidney disease - diagnosis and definition 
A routine blood test of creatinine in serum (S-) or plasma (P-) is a standard analysis in many 
clinical situations. Increased levels are often the first sign of kidney disease and kidney 
dysfunction. Creatinine, however, is affected by factors such as muscle mass, age, and 
hydration status which is why measuring or estimating glomerular filtration rate (GFR) is 
more reliable. The “golden standard” to measure GFR is inulin-clearance and iohexol 
clearance but they are both rather cumbersome methods. Estimation formulas based on 
creatinine and/or cystatin C have been developed for clinical use (75-77).  
Kidney disease as well as CKD are divided in five GFR groups according to criteria from 
Kidney Disease: Improving Global Outcomes (KDIGO):  
• normal GFR but with signs of kidney disease such as urinary abnormalities for 
instance proteinuria/ CKD 1 (GFR>90 ml/min/1.73m2 )  
• mildly decreased GFR/ CKD 2 (GFR 60-89 ml/min/1.73 m2)  
• moderately decreased GFR/ CKD 3 (GFR 30-59 ml/min/1.73 m2) 
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• severely decreased GFR/CKD 4 (GFR 15-29 ml/min/1.73 m2) 
• kidney failure7CKD 5 (GFR < 15 ml/min/1.73 m2 ) (75).  
Kidney disease is also typically divided in 
acute kidney injury (AKI), acute kidney 
disease (AKD) and chronic kidney disease 
(CKD)   
Fig 4. Kidney disease divided in AKI, AKD and CKD 
and the overlap of conditions
2.4.4 Acute kidney injury 
Acute kidney injury (AKI) is a very common event in hospitalized patients and mortality is 
increased irrespective of the underlying cause (78-81). Definition of AKI according to 
KDIGO is;  
• Increase of creatinine ≥ 26,5mol/L within 48 hours or  
• Increase of creatinine > 1.5 x baseline assumed or known to have occurred within the 
prior 7 days or 
• Urine production < 0,5 ml/min/kg/h for six hours (75) 
Risk factors for AKI are dehydration/hypovolemia, high age, heart failure, CKD, diabetes, 
and anemia (81-84). Triggers of AKI are often divided in; pre-renal causes such as sepsis, 
shock, malignant hypertension, intoxication, and surgery; post-renal causes such as 
hydronephrosis, malignancies, and infections, and renal causes for instance vasculitis, rapidly 
progressive glomerulonephritis, and toxicity to the kidney e.g. nephrotoxic drugs (80, 81). 
AKI often leads to acute tubular necrosis that is a clinical event when the tubular epithelium 
is damaged and loses its function. AKI can heal and kidney function be restored. However, 
depending on the cause and magnitude of the injury and/or preexisting renal failure, there 
may be a permanent decrease in kidney function (85) (Fig. 5).   
      
             Fig. 5 Acute kidney disease and renal recovery. (RRT-renal replacement therapy, SCr-serum creatinine)                
.            consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Y Chawla et al. (85).   .     
.            Open access 
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2.4.5 Chronic kidney disease 
CKD implies persistent changes in morphology and function of the kidneys for more than 3 
months (KDIGO). CKD is, as previously described, divided into 5 stages that is based on 
GFR. 
Advanced CKD often involves a number of disturbances such as fluid volume overload, 
electrolyte imbalances, anemia, malnutrition, CKD–mineral and bone disorder but also 
includes cognitive dysfunction and chronic inflammation (86, 87). Untreated chronic 
inflammation per se, contributes to cardiovascular morbidity and mortality in dialysis patients 
(87, 88). Pre-dialysis fluid overload is also associated with inflammation (89).  
Progression to CKD 5 and end-stage renal disease (ESRD) is followed by initiation of renal 
replacement therapy (RRT). Either hemodialysis (HD), peritoneal dialysis (PD), or kidney 
transplantation. The Swedish Renal Registry (SRR) coverage rate for RRT patients is nearly 
100 percent and reports annually epidemiology, prevalence, incidence, and several quality 
parameters. Figure 6 shows the underlying diseases for CKD among all RRT patients (9918 
persons) included in the registry in December 2017 (12). 
 
Fig. 6 Prevalent patients in RRT by diagnosis (%). Glomerulonephritis 25%, diabetes nephropathy 18%, Aduöt 
polycystic kidney disease 11%, Hypertension 10%, Pyelonephritis 4 %, Uremia without specification 10% and 
others 23 %. SRR Annual report 2018. Reprinted with permission from MedSciNet AB. 
2.4.6 Chronic kidney disease and inflammation 
The prognosis and outcome for CKD and ESRD-patients is partly dependent on the 
underlying disease but, there is a substantial impact of inflammation both in CKD 
progression, co-morbidity, and mortality. Inflammation in CKD was described to be 
associated with CVD and mortality at the end of the last century. Since then it has become 
clear that inflammation is an entity per se in CKD (90, 91). The causes behind increased 
inflammatory activity in CKD patients are numerous, e.g. underlying diseases, lifestyle 
factors, reduced elimination of cytokines due to renal failure, metabolic acidosis, and more 
(92). The uremic environment induces oxidative and carbonyl stress and substantially 
promotes inflammation (93, 94). Reduced levels of both 25-hydroxy vitamin D and 1,25-
dihydroxycholecalciferol similarly affects the functionality of both the innate and adaptive 
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immune system (95). Studies have shown that IL-6 is the best predictor of all-cause mortality 
and CVD mortality even though CRP, IL-1, TNF, and other have an impact and similarly an 
negative correlation to GFR (96-98). 
Malnutrition and protein wasting in CKD are explained by several factors e.g. depression and 
anorexia because of circulating cytokines in the brain, and suppressed levels of anabolic 
hormones. Malnutrition and protein wasting are also shown to be driven by persistent 
inflammation (99, 100). Moreover, inflammation maintain anemia in CKD-patients which is 
further amplified by decreased synthesis of EPO and lower responsiveness to EPO in the 
bone marrow (101).  
2.5 HYPERTENSION 
2.5.1 Definition and pathophysiology 
According to 2018 European Society of Cardiology (ESC) and European Society of 
Hypertension (ESH) guidelines, hypertension is defined as an office systolic blood pressure 
(SBP) of  ≥ 140 mmHg and/or diastolic blood pressure (DBP) of ≥ 90 mmHg, independent of 
age, sex, and comorbidities (102). BP should be measured with auscultatory or oscillometric 
semiautomatic or automatic sphygmomanometers at two separate visits (103).  
The historical explanation of the cause of both hypertension and the origin of hypertension 
related organ damage has mainly been focused on a viscous circle of sustained sympathetic 
activation and the mechanical wear of the blood vessels causing arterial stiffness and cardiac 
damage (104). Heart rate, HRV, and blood levels of norepinephrine (NE) have traditionally 
been used to quantify the adrenergic activity in hypertension (64). In addition to the ANS 
other “intrinsic” regulators such as the RAAS and the Endothelin-systems have crucial role in 
blood pressure pathophysiology.  
Studies have shown that muscular sympathetic nerve activity (MSNA), measured as burst per 
minute with microneurography, gives further information about the development of EHT. A 
meta-analysis showed that EHT patients had higher MSNA both when untreated and treated 
with antihypertensive drugs, suggesting that they did not fully obtain a normal circulatory 
sympathetic drive despite therapy (105). In other studies the MSNA was inversely related to 
HR which may indicate an greater parasympathetic (vagal) impact of HR than previously 
assumed (106).  
2.5.2 Hypertension and placental growth factor 
Placental growth factor (PlGF) is an angiogenic growth factor of the Vascular Endothelial 
Growth Factor (VEGF) family. It has pro-angiogenic effects on the fetoplacental circulation 
and supports trophoblast growth. Circulating PlGF levels depend on gestational age during 
pregnancy and particularly lower levels are associated to preeclampsia. It has been 
demonstrated that PlGF interacts with a neuro-immunological pathway in the spleen which 
suggests a potential immunological trigger of hypertension (107-109). 
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A novel mechanism relying on the neurosplenic sympathetic drive using a 
deoxycorticosterone acetate (DOCA)-salt hypertensive animal model has been shown to 
contribute to increased BP. DOCA-salt challenge in this model, significantly amplified PlGF 
expression in the spleen, which adds further clues to a neuro-splenic immune system 
involvement (110).  
2.5.3 Hypertension and renal denervation 
According to ESC/ESH 2018 guidelines resistant hypertension is to be considered when a 
treatment strategy consisting of appropriate modification of lifestyle measures and treatment 
with optimal or best-tolerated doses of three or more drugs, which should include a diuretic, 
is ineffective in lowering office SBP and DBP values to < 140 mmHg and/or < 90 mmHg, 
respectively (102).  
Modulation of renal sympathetic nerve activity through catheter-based radiofrequency 
ablation in resistant hypertension in humans was first described in 2009 (111). In the 
European Symplicity-2 study this invasive add-on treatment was evaluated. Primary endpoint 
was office BP reduction (≥ 10 mmHg) at 6-months after denervation and was achieved in 80-
90 % of patients without altering renal function (112). However, the Symplicity-3 study, 
conducted in the United States, that compared renal denervation with a sham procedure, 
failed to demonstrate a significant BP effect (113). Hence the use of RDN ended in most 
countries but the research did not. Two randomized trials aiming at renal denervation in 
hypertensive patients off any medication (SPYRAL HTN-OFF MED) or on (SPYRAL HTN-
ONMED) demonstrated a significantly BP decrease at 3 months using a multielectrode 
catheter (114, 115). In 2018 the RADIANCE-HT-SOLO showed that endovascular 
ultrasound RDN reduced BP at 6 months requiring fewer antihypertensive medications 
compared with a sham control. 
ESC/ESH 2018 guidelines do not currently recommend invasive device-based treatment but 
are awaiting ongoing trial results for future guidance. 
2.5.4 Hypertension and inflammation 
Over the last decades it has become more evident that the immune system plays an important 
role in both pathogenesis and maintenance of EHT. There are several experiments that 
illustrate the role of different immune cells in hypertension. Models of salt-depending 
hypertension or angiotensin II (ang II) induced hypertension have shown that dysfunctional 
monocytes/macrophages are protective (116-118). Furthermore, thymectomy in hypertensive 
models reduces BP (119, 120) Patients with human immunodeficiency virus and no anti-viral 
medication are less likely to develop hypertension as compared to HIV-negative individuals, 
or HIV-positive subjects with highly active antiretroviral therapy (HAART) (121). Another 
study demonstrated that hypertension was not developed in a model with a deficient gene 
transcoding enzyme resulting in lack of B and T-cells, when exposed for Ang II (122). T-cells 
have been shown to moderate endothelin dysfunction and microvascular injury caused by 
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Ang II. Lack of regulatory T-cells have been shown to exaggerate Ang II-induced 
microvascular injury by modulating innate and adaptive immune responses (123) 
In figure 7 the role of immune cells that can trigger and maintain hypertension is illustrated. 
Environmental factors and genetic susceptibility lead to a small BP augmentation by 
activating the SNS and inhibiting the PNS. High BP and/or pro‐hypertensive stimuli induce 
tissue injury that leads to development of Damage-associated molecule patterns (DAMPs). 
DAMPs activate innate immunity via toll-like receptors (TLR) on type 1 macrophages (M1), 
type 1 dendritic cells (DC1) and natural killer (NK) cells. Innate immune cells contribute to 
inflammation, both directly and via adaptive immunity and the production of autoantibodies, 
leading to vascular injury that closes the pro‐hypertensive loop which is a feed‐forward 
process resulting in progressive BP elevation. Throughout this process, anti‐inflammatory 
cells could provide homeostatic fine‐tuning of the inflammatory process in blood vessels and 
the kidney. However, this anti‐inflammatory mechanism could be rendered incapable of 
counteracting the development of hypertension because of factors such as Ang II. PAMPs are 
Pathogen-associated molecular patterns derived from bacteria, viruses, and other micro-
organisms (124, 125). 
                           
Fig 7. The viscous circle of hypertension and inflammation. Caillon (124). Reprinted with permission from 
Whiley and Sons 
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2.6 THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY 
2.6.1 The vagus nerve 
Vagus means wandering and the parasympathetic vagal nerve is the longest and most 
widespread of all nerves in the body. The vagus nerve is the 10th cranial nerve and is a mixed 
nerve meaning that it carries both sensory afferent (80%) and efferent motor fibers (126). 
Vagus is vital as it provides parasympathetic innervation to all thoracic organs and almost all 
subdiaphragmatic, visceral organs. The axons to the thoracic organs are coated with myelin 
which makes the signal transport fast whereas the axons to visceral organs are unmyelinated 
and hence slower (38, 127).  
The afferent axons send sensory signals from the visceral organs and terminate in the Tractus 
Solitarius in the brainstem where signals are subsequently forwarded to other structures in the 
brainstem, thalamus and the forehead areas. The efferent motor vagus neurons begin in the 
dorsal motor nucleus (DMN) and the nucleus ambiguus (NA) in the medulla oblongata. The 
parasympathetic axons meet and interact with postganglionic neurons in the ganglia in the 
proximity of or in the target organ (34, 36).  
2.6.2 Description of the cholinergic anti-Inflammatory pathway 
In a highly cited paper in Nature 2002, K Tracey 
and co-workers, described the CAP and the anti-
inflammatory reflex for the first time. In case of 
injury, inflammation, ischemia, or infection signals 
are relayed to the central nervous system via the 
sensory afferent vagus nerve. An activating response 
is subsequently initiated and returned via the 
efferent motor part of the vagus nerve, referred to as 
the inflammatory reflex (Fig. 8) (26). In a proof-of-
concept study is was demonstrated that VNS 
attenuates the systemic inflammatory response to 
endotoxin (128, 129). Since these seminal papers were published continued research in the 
field has delineated many of the detailed meticulous mechanisms and substances involved 
in this neuroimmune pathway. Fig 8 CAP 2002 Tracey (26). Reprinted with permission from Springer 
Nature 
The efferent motor vagus terminates in the sympathetic celiac plexus where the splenic nerve 
is activated. (130, 131). Specialized T-cells, with the ability to produce the enzyme 
acetylcholine transferase (ChAT-cells), are located in the red pulp and marginal zone of the 
spleen (132). ChAT-cells are stimulated by beta-adrenergic receptors that binds NE 
originating from the splenic nerve. Activated ChAT-cells synthesize and release acetylcholine 
that binds to an α7nAChR on macrophages and thereby downregulates TNF release. Released 
NE also inhibits B-cell migration and antibody production (132-135) (Figure 9).  
  24 
 
Fig 9. Hosoi (133) Reprinted with permission from John Wiley and Sons 
In addition to receptors for inflammatory cytokines, afferent nerve endings have PRR, such as 
TLRs for PAMPs and DAMPs and receptors for serotonin, histamine, prostaglandin, and 
nerve growth factor (136, 137). There are also nociceptive receptors, but their signal reaches 
primarily the CNS (138, 139). Adrenergic and acetylcholine receptors are expressed by 
immune cells and facilitates neuroimmune communication (140-142). Immune cells can, in 
addition to neuro transmitter substances as acetylcholine, also synthesize dopamine and 
catecholamines and thereby participate in the local regulation of neuroimmune signaling 
(135, 141).  
The role of α7nAChR has furthermore been examined in several studies, for example in an 
α7nAChR depleted mice model. When inducing arthritis in this model by immunization of 
collagen II, the α7nAChR depleted mice showed milder arthritis and cartilage destruction as 
well as a decrease in T-cells in lymph nodes. This result indicates that the α7nAChR has an 
important role in the regulation of inflammatory response as well as in T-cell dependent 
reactions both in the innate and adaptive immune system response (32).  
2.6.3 Vagus nerve stimulation 
Neuromodulation by vagus nerve stimulation (VNS) was first recorded in the late 1800’s 
when it was observed that mechanical stimulation of the vagal region suppressed seizure 
activity (J. Corning, Prolonged instrumental compression of the primitive carotid artery as a 
therapeutic agent., Med. Rec. 21, 173–174 (1882)). 
VNS by physiological and pharmacological modalities has been studied in several animal 
models and has been shown to attenuate inflammatory markers such as High mobility group 
Box-1 protein (HMGB1) and TNF in models of inflammation, including collagen induced 
arthritis (128, 129, 140, 143).  
Cholinergic analogues, such as GTS 21, have been used to explore how CAP performs in 
different experiments simulating clinical situations. In a model of endotoxemia, 
administration of GTS 21 improved survival and reduced TNF in treated animals as 
compared with controls (143). In a pancreatitis model histological score was improved and 
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IL-6 in the circulation was decreased (144). Similarly, in a model of renal ischemia, GTS 21 
decreased TNF levels in kidney tissue and reduced tubular necrosis (145). 
2.6.3.1 Invasive vagus nerve stimulation 
VNS, with an implantable device, was approved by the US 
food and drug administration (FDA) in 2002 as a treatment 
for drug resistant epilepsy (146, 147). The implantable 
device is a battery driven stimulator with a wire electrode 
attached around the left cervical vagus. In 2005 the 
approval was expanded to include treatment of resistant 
depression (Fig. 10) (148). The effect in the CNS of VNS 
is, in brief, an alteration of signaling/transmission in the 
prefrontal cortex area, midbrain, and hindbrain where NE        Fig 10. Schematic drawing of                                                        
and serotonin are transmitter substances (149).                          implantable  VNS. Verrier (150).                       
.                                                                                                                          Open  access.  
Recent clinical studies have shown that electrical or electromagnetic energy via cervical 
implants stimulating the vagus nerve may be beneficial for patients with inflammatory 
diseases such as RA (151, 152) and Crohn’s disease (153, 154). In animal models of heart 
failure, VNS has shown positive results for long-term survival (155), while a recent clinical 
study, (INOVATE-H) in 707 patients with heart failure followed for a treatment for a mean 
of 16 months, did not confirm any beneficial effect of VNS on survival (156). Models of 
myocardial ischemia-reperfusion damage have shown better outcome after VNS although 
results have not been consistent in other models (157).  
2.6.3.2 Transcutaneous vagus nerve stimulation 
Electrical transcutaneous VNS (tVNS) can be directed to the outer ear, where the auricular 
branch of vagus has sensory fibers, or at the cervical vagus. In 2011 a tVNS device for 
electrical stimulation of the auricular branch of vagus was approved in Europe for treatment 
of drug resistant epilepsy (158). This device has also been used in clinical trials of depression 
and pain (159, 160) (Fig. 11a). TcVNS Gammacore, stimulates the cervical vagus and was 
approved in Europe in 2013 and by FDA in 2017, for the treatment of migraine and cluster 
headache (Fig. 11b) (161). 
      
Fig. 11a tVNS device NEMOS®. 
(158)        
Fig. 11b tcVNS Gammacore. 
Practical Neurology. Reprinted 
wih permision from Elsevier. 
Open access (162).  
In a recent study by De Couck et.al the effect of auricular tVNS in healthy subjects was 
studied, focusing on HRV as an indirect measure of vagal activity. The study showed that 
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short term (10 min) left versus right ear tVNS versus sham resulted in significant increases 
only in SDNN. Prolonged tVNS, (1 hour) in the right ear, significantly increased the LF and 
LF/HF components of HRV and SDNN in women, but not in men (163). 
In a study by Addorisio et al. a vibrotactile device was used to bring vibrations to the cymba 
choncha of the outer ear. Both healthy subjects and patients were treated and resulted in 
modulation of peripheral blood cytokine levels in healthy subjects and lowering of TNF 
levels and disease activity in patients (164). 
2.6.3.3 Drug mediated vagus nerve stimulation 
The idea of pharmacological stimulation of vagus is not new but quite recently a randomized, 
double-blind, placebo-controlled study was published. Galantamine is a centrally acting 
acetylcholine esterase inhibitor and typically prescribed to prevent progression of 
Alzheimer´s disease. Galantamine, with anti-inflammatory activity and known to active CAP, 
was given to patients with metabolic syndrome. Galantamine treatment for 12 weeks was 
shown to alleviate inflammation and alter HRV as well as lowering plasma insulin and 
insulin resistance (165).  
 
3 AIM OF THE STUDIES 
The aim of this thesis was  
 
1. To study the functionality of the cholinergic anti-inflammatory pathway/CAP in 
hemodialysis patients and peritoneal dialysis patients, compared to controls, using a whole 
blood inflammation model. 
2. To explore the hypothesis that patients undergoing RDN due to treatment-resistant 
hypertension would respond with reduced cytokine release through decreased sympathetic 
nerve activity.  
 
3. To investigate if short-term VNS, using a minimally invasive method, could improve 
inflammatory cytokine levels and alter vagal tone (HRV) in hemodialysis patients. 
4. To investigate correlations between inflammatory markers and HRV indices in a freely 
available database (HeartBEAT). To calculate the optimal length of an ECG recording that 
are needed when utilizing HRV methodology for predicting elevated levels of inflammatory 
markers.  
 
4 STUDY SUBJECTS AND METHODS 
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4.1 STUDY SUBJECTS 
4.1.1 Study I – The cholinergic anti-inflammatory pathway activity in 
dialysis patients: a role for immunomodulation? 
Patients were recruited among chronic dialysis patients at the Renal Department at 
Karolinska University Hospital, Huddinge. Healthy controls were recruited among staff at the 
Renal Department at Karolinska University Hospital, Huddinge. Both patients and healthy 
controls were included by Marie Hilderman.  
Inclusion criteria for patients were: 
• RRT with hemodialysis (HD) or peritonealdialysis (PD) regardless of underlying 
disease.  
• Stable dialysis procedures. 
• No clinically significant symptoms of infection or inflammation. 
• Ability to understand oral and written study information. 
Inclusion criteria for healthy controls were: 
• No significant history of inflammatory disease. 
• No clinically significant symptoms of infection or inflammation. 
• Ability to understand oral and written study information. 
4.1.2 Study II – The Cholinergic anti-inflammatory pathway in resistant 
hypertension treated with renal denervation 
All patients and disease controls were recruited at the hypertension clinic at Södersjukhuset, 
Stockholm by cardiologists Nils Witt, Christina Jägrén and Joakim Olbers.  
Inclusion criteria for patients were: 
• Office SBP > 160 mmHg despite the use of at least three anti-hypertensive drugs, 
including a diuretc, at maximum tolerated doses.  
• No current clinical signs of infection or inflammation. 
• Ability to understand oral and written study information. 
Exclusion criteria for patients were: 
• Renal artery stenosis. 
• Secondary hypertension. 
Inclusion criteria for disease controls were: 
• Stable patients scheduled for elective coronary angiography due to ischemic heart 
disease. 
• No current clinical signs of infection or inflammation. 
• Ability to understand oral and written study information. 
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4.1.3 Study III – Minimally invasive vagus nerve stimulation in 
hemodialysis patients and inflammatory response 
The study population was recruited consecutively among stable chronic hemodialysis patients 
at the Dialysis Department at Karolinska University Hospital, Huddinge between November 
2014 and November 2015. All patients were included by Marie Hilderman. 
Inclusion criteria were: 
• RRT with hemodialysis regardless of underlying disease.  
• Stable dialysis procedures. 
• No clinically significant symptoms of infection or inflammation. 
• Ability to understand oral and written study information. 
4.1.4 Study IV – Prognostic potential of heart rate and heart rate variability 
for monitoring the cholinergic anti-inflammatory pathway 
4.1.4.1 Data source 
The database Heart Biomarker Evaluation in Apnea Treatment (HeartBEAT) has been made 
accessible by the National Sleep Research Resource (NSRR, sleepdata.org) USA. 
HeartBEAT is a randomized controlled trial that assesses the effects of supplemental 
nocturnal oxygen or Continuous Positive Airway Pressure (CPAP) therapy, compared to 
optimal medical preventive therapy in patients with CVD or CVD risk factors and moderate 
to severe OSA or history of snoring.  
Inclusion criteria were: 
• Established Coronary Artery Disease or established CVD risk factors. 
• Home sleep test that showed moderately severe sleep apnea. 
Exclusion criteria were: 
• Poorly controlled health. 
• Current use of supplemental oxygen or CPAP for OSA. 
4.1.4.2 Study subjects 
Three-hundred and eighteen patients aged 45-75 were included. The protocol for the trial 
consisted of 3 arms and subject were randomized to:  
1. Healthy Lifestyle and Sleep Education (HLSE).  
2. HLSE and education in CPAP treatment and usage of it for 3 months.  
3. HLSE and supplemental oxygen during sleep for 3 months.  
 
All patients received medical preventive therapy according to current American Heart 
Association guidelines for prevention of CVD and sleep guidelines. Patients were sampled 
twice; at baseline and at 3 months when 301 patients remained. The HeartBEAT database 
contains a large amount of widely different parameters e g socioeconomic status, medication, 
body composition, blood pressure, blood glucose, and lipid status. Characteristics of patients, 
outcomes, and results are described in detail elsewhere (166-168). For this study we used 
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nocturnal ECG-recordings and available inflammatory markers such as CRP, TNF, IL-6, and 
E-selectin. Fifty-six patients were not analyzed for HRV because of missing or noisy ECG 
within the target length of recording (6 ± 2 hrs).  
4.2 METHODS 
4.2.1 Blood sampling and ECG Study I-III 
4.2.1.1 Study I 
All subjects were sampled in the morning. HD-patients were sampled before dialysis. In 
patients treated with Continuous ambulatory peritoneal dialysis (CAPD)-patients the 
sampling was timed to the night bag and first day bag exchange in the morning. In patients 
treated with Ambulatory peritoneal dialysis (APD) samples were collected in the morning 
after the end of the APD session. A quiet examining room outside the Dialysis Department 
was used for ECG recordings, which were done at a separate visit with the subjects in a 
supine position in a bed.  
4.2.1.2 Study II 
All subjects were sampled before treatment/intervention (RDN or Coronary Angiography 
(CA)) in the morning at the PCI- (Percutaneous coronary intervention) unit at the Cardiology 
Department at Södersjukhuset, Stockholm. ECG was recorded at the same occasions with the 
patient in a supine position in a bed. Blood samples and ECG were again collected the day 
after intervention in all subjects. RDN-patient were then followed with blood samples and 
ECG at 3 and 6 months. 
4.2.1.3 Study III 
In this study all patients had blood drawn after ECG recording, but before intervention 
treatment at the Dialysis Department at Karolinska University Hospital Huddinge. Blood 
samples were collected when dialysis needles were inserted. ECG recordings were done in a 
quiet examining room outside the Dialysis Department with the patients in a supine position. 
These procedures were repeated during the treatment period after 2 and 4 weeks, and at 
follow up at 8 and 12 weeks (Fig. 12).  
4.2.2 Whole blood assay Study I-III 
4.2.2.1 Blood samples  
Whole blood was collected into two heparinized tubes and immediately kept in a 37°C heated 
container until processed within 60-120 min. A non-heparinized tube was left to clot for 2 
hours at room temperature (approximately 25° C) and subsequently centrifuged (5-10 min, 
828 g [2000 rpm in Sorvall RT7 Plus centrifuge]). Five hundred μL aliquots of harvested 
serum were frozen at -80° C for pending analysis of basal cytokines.   
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Reagents: 
• Lipopolysaccharide (LPS) from Escherichia coli 0111:B4, Sigma-Aldrich (St Louise, 
MO, USA), cat.No. L4130 was used. Five mg LPS was solved in 1 mL phosphate 
buffered saline (PBS), sonicated for 30 min, vortexed well and diluted 5 times  to 
1x106 ng/mL (= stock solution) and then portioned and frozen at -80° C. The 1x106 
ng/mL stock solution of LPS was serially diluted with PBS to 10000 and 1000 ng/mL.  
• GTS 21, a cholinergic analogue was provided by Yousef Al-Abed who synthesized, 
isolated and standardized it. Yousef Al-Abed is a medicinal chemist and investigator 
at the Feinstein Institute for Medical Research. GTS 21 (2 mg) was diluted in distilled 
water to approximately 4.6 and 9.2 mmol/L working solutions, respectively. 
4.2.2.2 Whole blood model 
One mL of whole blood was pipetted into twelve 2 mL Eppendorf tubes. Ten µL of 
(phosphate buffered saline) PBS was added to tubes #1-4. 10 µL 4.6 mmol/L GTS-21 
working solution (final concentration approximately 45 µmol/L) to tubes #5-8; and 10 µL 9.2 
mmol/L GTS-21 working solution (final concentration. approximately. 90 µmol/L) to tubes 
#9-12. The tubes were incubated at 37°C for 15 minutes on a rocking platform. Then, 10 µL 
PBS was added to tubes #1,2,5,6,9,10; 10 µL of the 1000 ng/mL LPS (final concentration 10 
ng/mL) was added to tubes #3,7,11; and 10 µL 10000 ng/mL LPS (final concentration 
approximately. 100 ng/mL) was added to tubes #4,8,12. Thus, tubes #1-2 containing whole 
blood and PBS only, served as controls (Figure 12). 
After 4 h incubation at 37° C on a rocking platform, plasma was collected by centrifugation 
(2600 g, 20 min, 18° C, Eppendorf centrifuge 5804R) and frozen at -80° C pending cytokine 
analyses. 
 
 
Fig. 12. Schematic presentation of the whole blood assay with different concentrations of LPS and GTS 21. 
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4.2.3 Cytokine analysis Study I-III 
High sensitivity TNF, IL-1, IL 6 (Study I), and IL-10 were analyzed on an Immulite 1000 
Analyzer from Siemens using immunometric assays (Siemens Healthcare Diagnostics, Los 
Angeles, CA, USA) according to the instructions of the manufacturers. PlFG was analyzed 
using ELISA kit from R&D Systems (R&D Systems Europe Ltd. Abingdon, UK). 
4.2.3.1 ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a method for detecting and quantifying 
proteins, peptides, antibodies, and hormones. ELISA uses antigens, antibodies, enzyme-
linked antibodies, and a solution with catalyzing substrate for activation of enzyme. There are 
two principle methods of ELISA; (169) in the direct coating method, the molecule of interest 
is diluted and directly attached to the inner surface of the wells of a microtiter plate by 
passive adsorption. In the indirect coating method, also called “capture” or sandwich ELISA, 
labeled antibodies or antigens precoats the wells. Serum, plasma, or cell culture supernatant 
with the molecule of interest is added to the wells and then unbound molecules are washed 
away. An enzyme-linked antibody is added, and in the last step, a solution with a reagent 
activates the enzyme which then produces fluorescent light. The intensity of the color 
quantifies the levels of the primary antibody or antigen. In study I-III the “sandwich” ELISA 
was used to quantify TNF, IL-1, IL-6, IL-10, and PlGF.  
4.2.4 Routine blood samples Study I-III 
High-sensitivity C-reactive protein (hsCRP), hemoglobin (Hb), white blood cell counts 
(WBC) with differentials, Creatinine, Potassium, and Sodium were analyzed by using routine 
methods at the Department of Clinical Chemistry at Karolinska University Hospital (study I 
and III) or at the Department of Clinical Chemistry at Södersjukhuset (Study II).   
4.2.5 Heart rate variability Study I-III 
HRV and thoracic bioimpedance (TBI) were recorded at the same time points as blood 
sampling (except in study I). ECG for HRV was recorded by using 3 gel coated electrodes 
positioned on the right hand, right leg and left leg. TBI was measured with 4 gel coated 
electrodes on the right and left side under the chest. The lower electrodes were used for 
current injection and the upper ones for voltage measurement. Before ECG recording patients 
performed one minute of controlled breathing (10-15 breaths per minute depending on patient 
comfort) to adjust for any incongruence in breathing pattern.  
ECG and TBI were recorded for 20 minutes by using a custom-made device designed by Z-
Health Technologies AB, Borås. The RR intervals variability were automatically calculated 
based on the Pan-Tompkins algorithm (170) implemented in Matlab 2015, MathWorks, 
Natick, Massachusetts, USA. The subsequent HRV analysis generated data for time and 
frequency domain parameters in accordance with European Task Force for HRV 
measurements (59). Time domain parameters e.g. SDNN were calculated as an overall 
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estimate of HRV and frequency domain were calculated with focus on LF, HF and LF/HF-
ratio. TBI recordings were used to calculate the respiration rate and to check for respiratory 
sinus arrhythmia (RSA) as a source of difference in frequency analysis. 
4.2.6 Renal denervation and coronary angiography Study II 
4.2.6.1 Renal denervation 
RDN was performed at the PCI unit at the Cardiology Department at Södersjukhuset, 
Stockholm. RDN patients received pre-treatment with diazepam and peri-procedural 
analgesia with an i.v. infusion of remifentanil. Antithrombotic treatment included Aspirin (a 
bolus dose of 320 mg at least 12 h prior to the procedure, followed by 75 mg o.d.) and a peri-
procedure administration of a weight-adjusted dose (50-100 U/kg) of unfractionated Heparin 
(UFH) with a target activated clotting time (ACT) of 250 seconds.  
Femoral artery access was established using standard 8 French (F) sheaths and guiding 
catheters were advanced to select left and right renal artery position. Radiofrequency ablation 
was performed bilaterally at a minimum of 6 locations in each renal artery using the 
EnligHTN™ multi-electrode renal denervation catheter (St Jude Medical, St Paul, MN, 
USA). In the presence of multiple renal artery anatomy, all branches with a diameter of > 4 
mm were treated. For post-procedure hemostasis, an arterial closure device (8F Angio-
Seal™, St Jude Medical, St Paul, MN, USA) and provisional manual compression was used. 
Following the procedure, patients were monitored in hospital for 24 h with pre-discharge 
evaluation of BP, arterial access site hemostasis and renal function. 
4.2.6.2 Coronary angiography 
CA was performed at the PCI unit at the Cardiology Department at Södersjukhuset, 
Stockholm. The procedure was performed with standard 6F sheaths and catheters through 
right radial artery access. All 4 disease controls received pretreatment with Aspirin (a bolus 
dose of 320 mg at least 12 h prior to the procedure, followed by 75 mg o.d.), paracetamol and 
diazepam. In the presence of coronary artery disease, a clinical decision on revascularization 
strategy was made. Standard procedure included implantation of drug eluting stents (DES) 
and the addition of antithrombotic treatment with a weight adjusted dose of low-molecular-
weight-heparin (LMWH) as well as a second oral anti-platelet drug (Clopidogrel, loading 
dose of 600 mg followed by 75 mg o.d.). Post-procedure monitoring of BP, hemostasis and 
renal function were similar to that in RDN patients. 
4.2.7 Minimally invasive oscillating device Study III 
A Minimally invasive oscillating device developed for a rhinitis and a migraine study was 
used (171, 172). The VNS equipment consisted of a manually operated electric energy unit 
and a single-use plastic tube with an inflatable tip (Fig. 13a). The inflatable tip was made of 
thin latex and fixed at the end of the tube with a strong rubber band. Inside the latex tip there 
was a soft thin plastic pin anchored to the edge of the tube. The tip was lubricated with water 
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and manually inserted in the left nostril and a headband was used to secure the position of the 
tub and tip (Fig 13b). 
 
             a)      b)  
Fig. 13 The minimally invasive oscillation device. a) The catheter with inflatable tip b) The catheter inserted in 
left nostril and secured in position by special designed headband. Juto (171). Open access 
 
In study III the tip was inflated with air at a pressure of 95 mbar to fill out the nostril. In case 
of major deviation in nose cavity volume it was possible to adjust the size of the tip by 
moving the rubber band. A 25 mm soft pin inside the tip was set to oscillate at a frequency of 
68 Hz. With the balloon in direct contact to the mucosa the study subjects sensed the 
oscillation as vibrations in their nose and forehead. Each treatment session lasted for 10 
minutes. The choice of side, pressure, frequency, and standardized duration of treatment was 
made in discussion with the designer of the VNS equipment based on prior studies using the 
same device (171, 172). 
4.2.8 Study IV 
The HeartBEAT data was prepared as follows: ECG recordings were available from two 
timepoints, 318 at baseline and 301 at follow-up. Twenty-four ECG recordings from baseline 
and 32 ECG from follow-up were excluded due to short or noisy ECG within the target 
recording length (6±2 hours). Baseline and follow-up ECG were put together to a data set of 
563 ECG-recordings. Each ECG recording was divided in 5, 10, 30, 60, 90, 120, 180, and 
360 minutes epochs. Pre-processing was performed to remove powerline interference, reduce 
baseline wanders and high frequency noises by use of appropriate notch and bandpass filters. 
Processing and signal analysis were performed using custom scripts in MATLAB 2014a, 
(MathWorks Inc. Natick, Massachusetts, USA). R-peaks were detected and RR intervals 
calculated by using the Pan-Tompkins method (173).  
HRV analysis was conducted using a selection of conventional HRV indices in the time 
domain, frequency domains, and the non-linear methods described by the Taskforce for HRV 
measurement and analysis (174). HRV indices were calculated for ECG epochs of 5, 10, 30, 
60, 90, 120, 180, and 360 minutes. 
Correlation between HRV indices and inflammatory markers (CRP, TNF, IL-6, E-Selectin) 
were computed by Pearson correlation coefficient controlling for potential confounding 
factors. Both inflammatory markers and skewed HRV indices  (SDNN, SDANN, RMSSD,  
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HR, LF, HF, VLF, SD1, and SD2) were transformed by natural logarithm (ln) to attain 
normal distribution. This calculation was repeated for all 5, 10, 20, 30, 60, 120, 180, and 360 
minutes epochs.  
 
The prediction value of HR and HRV indices (SDNN, SD2) in combination with individual 
characteristics (age, gender, BMI and betablocker) was calculated in a hierarchical 7-level 
model using multiple regression and least squares regression. Level 1 used only the mean 
HR, level 2 added the SDNN, level 3 added the non-linear index SD2, and levels 4-7 
included the individual characteristics; age, gender, BMI, and beta-blocker, respectively.  
 
For detection of differences between HRV comparing patients with CRP < 5 mg/mL and 
CRP ≥ 5 µg/mL an independent two-sample student t-test was used. To compensate for an 
unbalanced distribution (more cases with CRP <5 µg/mL) a weighted least squares regression 
was used by giving higher weights to values with less probability.  
4.2.9 Statistics 
4.2.9.1 Study I 
Comparisons between groups were performed using non-parametric Wilcoxon’s test. 
Comparisons between groups and various concentrations of LPS were performed using 
Friedman’s non-parametric two-way ANOVA. Fischer’s exact test and chi-square tests were 
used for categorical variables. Non-parametric Spearman’s rank correlation analysis was used 
to determine associations between various variables.  
4.2.9.2 Study II 
Difference between two groups were assessed with the non-parametric Wilcoxon test for 
continuous variables and Chi-square test (Fischer’s exact test) for ordinal/nominal variables. 
Comparisons between more than two groups were assessed with non-parametric ANOVA 
Kruskal-Wallis test for continuous variables. We performed no adjustments for multiple 
comparisons i.e. Bonferroni procedures. 
4.2.9.3 Study III 
Comparisons between four time periods were assessed with nonparametric analysis of 
variance Kruskal -Wallis ANOVA test. 
Statistical analysis in study I-III were performed using statistical software SAS version 9.4 
(SAS Campus Drive, Cary, NC, USA). 
4.2.9.4 Study IV 
See description of method in chapter 3.2.8. Analyses were performed using SPSS Statistics 
23 (IBM Inc., New York, USA) following the Leard Statistics guidelines (175).  
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5 RESULTS 
5.1 STUDY I – THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY 
ACTIVITY IN DIALYSIS PATIENTS: A ROLE FOR IMMUNOMODULATION? 
A total twenty patients with CKD 5 and RRT were included. The cohort comprised twelve 
patients (7 male and 5 female, age range 26-84 years) on HD treatment and eight patients (5 
male and 3 female, age range 47-84 years) on PD treatment. Patients in HD were treated 3 
times per week on average 4 hours per dialysis session, whereas PD patients were treated 
with standard CAPD regimen except for two who used APD. Eight healthy controls were 
included (5 male and 3 female, age range 31-52 years).There was a significant difference in 
age between patients and controls, but not in gender.  
5.1.1 Whole blood assay and routine blood samples 
CRP, TNF, IL-1, Il-6, and IL-10 were significantly increased at baseline in unstimulated 
blood samples in patients compared with controls (p=0.004, p=0001, p=0.02, p-0.004, 
p=0.002 respectively). After LPS stimulation with the concentrations of 10 and 100 ng/mL 
there was an increase of TNF and IL-6 levels though, significantly stronger in patients at 
maximal stimulation compared with controls (p<0.01). IL-1 and IL-10 was significantly 
increased in patients at both concentrations of LPS compared with controls (p<0.01). WBC 
and differentials did not differ between groups. 
In the presence of GTS-21 there was a strong decrease of TNF and IL-1 in patients that did 
not differ significantly from controls, but a statistical difference remained between groups 
with higher levels in patients (p<0.01). The same pattern for IL-6 was observed however 
without differing between patients and controls. IL-10 increased in the presence of GTS 21 in 
a dose-dependent manner, but only in patients. 
5.1.2 HRV 
HRV and TBI were recorded in a subset of the dialysis patients (7 in HD and 5 in PD) and in 
all 8 healthy controls. For practical reasons these recordings were not done at blood sampling 
but at a separate visit. Patients and controls were assessed in a quiet examining room and in a 
supine position. There were no significant differences for HRV indices between the HD and 
PD patients. The result of the HRV analysis in patients confirmed significant autonomic 
dysfunction compared to controls regarding time domain parameter SDNN, as well as the 
frequency domain parameters HF and LF. Respiration rate and heart rate did not differ 
between groups.   
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5.2 STUDY II – THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY IN 
RESISTANT HYPERTENSION TREATED WITH RENAL DENERVATION 
Ten patients with resistant hypertension were recruited as suitable for RDN (7 male and 3 
female, median age 62 years, age range 47-71 years). Four patients (3 male and 1 female, 
median age 66 years, age range 59-76 years) scheduled for elective coronary angiography due 
to ischemic heart disease served as DC. 
5.2.1 Whole blood assay and routine blood sample 
DC had significantly higher TNF and IL-1 than patients at baseline (p=0.009 and p=0.03 
respectively) but there was no difference in IL-10 levels. 
One day after RDN/CA the basal cytokine levels were unchanged in DC whereas there was a 
decrease of TNF in RDN-patients (p<0.03). LPS-stimulated levels of pro-inflammatory TNF 
and IL-1 were significantly lower 1 day after RDN (LPS 0, 10 and 100 ng/mL TNF; 
p=0.0009, p=0.0009, p=0.001, IL-1; p=0.0001, p=0.002, p=0.005 respectively). Anti-
inflammatory IL-10 levels were significantly higher on day 1 (p=n.s, p=0.02, p=0.01 
respectively). However, at 3 and 6 months the LPS-stimulated cytokine levels were similar to 
levels before RDN in the incubated 4 h samples. The stimulated cytokine levels in DC did not 
differ before CA and at day 1 after the procedure.  
In the presence of 90 μmol/L GTS-21 at day 1 after RDN, the TNF levels in LPS-stimulated 
blood exhibited an even more marked reduction (p<0.001), but these TNF levels also 
weakened during follow-up (Fig. 14). 
                                
Fig. 14. Levels of TNF in the LPS-model with LPS-concentrations 10 and 100 ng/mL and GTS 21 in 
concentrations 45 and 90 μmol/L. The effect of RDN (LPS 10+0 and LPS 100+0) was most pronounced one day 
after RDN but declined with time at follow up. The addition of GTS 21 (LPS 10 + GTS 90 and LPS 100 + GTS 
90) resulted further reduction of TNF. Hilderman (176). Reprinted with permission from Oxford University 
Press. 
5.2.2 HRV 
HRV indices (SDNN, RMSSD, HR, HF, LF/HF) did not show any significant changes in 
RDN patients on day1, or at 3 and 6 months. RDN patients however had lower HRV indices 
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as compared to norms established by the Task Force of the European Society of Cardiology 
and the North American Society of Pacing and Electrophysiology 1996, suggesting 
underlying autonomic dysfunction (59).  
5.2.3 Placental growth factor 
Baseline PlGF was similar in DC and RDN 
patients, but higher than in healthy controls. PlGF 
was subsequently measured at all time points in 
RDN patients but did not differ during follow-up. 
5.2.4 Blood pressure 
DBP was significantly lower one day after renal 
denervation (p=0.001) (Fig. 15). No further 
significant differences in BP were found. 
 
                           Fig 15 SBP and DBP at all time points. 
Additional figure not published in paper. Hilderman.(177)  
5.3 STUDY III – MINIMALLY INVASIVE VAGUS NERVE STIMULATION IN 
HEMODIALYSIS PATIENTS AND INFLAMMATORY RESPONSE 
Twelve HD patients were enrolled consecutively between November 2014 and November 
2015 (8 male, 5 females; age range 47-86 years). See table 2 for clinical characteristics, blood 
chemistry, and medication. The primary kidney diseases are shown below in figure 16. All 
patients completed the 4 weeks protocolized intervention period, but 4 of the patients were 
affected by either infection or access surgery during follow-up. The intervention procedure 
was generally well tolerated except minor problems such as sneezing and lacrimal tear flow. 
There were no major adverse events during the intervention period. 
 
Sex female (%) 38
Age (years) 60 (49-82)
Vintage dialysis (months) 96 (16-233)
P-hsCRP (mg/mL) 6 (0.4-44.6)
B-Hb (g/L) 106 (97-113)
B-WBC (x109) 6.4 (4.8-10.2)
B-Monocytes (x109) 00.7 (0.4-1.0)
B-Lymfocytes (x109) 1.4 (0.8-1.9)
S-TNF (pg/mL) 20.3 (14.2-77.4)*  
S-IL-1 (pg/mL) 1.3 (0.3-9.2)*
S-IL-10 (pg/mL) 1.2 (0.8-2.6)*
B-blocker 6
Alfa-blocker 1
Cal channel antagonist 5
ACE/ARB- inhibitor 6
Furosemide 4
Statins 3
Patients (n=12)
Medications, patients
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Fig. 16 Underlying diseases, study III.
5.3.1 Whole blood assay and routine blood samples 
The levels of CRP and unstimulated cytokines did not change significantly during the study 
although there was a trend towards decreased CRP (ANOVA, p=0.61) and IL-1 (ANOVA, 
p=0.63) as well as increased IL-10 (ANOVA, p=0.37). In the whole blood assay, we saw a 
small trend of TNF and IL-1 reduction and increase of IL-10, during the intervention period 
however again without reaching statistical significance. In the presence of the cholinergic 
analogue, GTS 21, there was a further approximately 50% reduction of cytokine release. Here 
shown as TNF (Figure 17). We also analyzed the 8 patients that completed the study and 
follow-up without any hurdles separately. Although the TNF decrease was slightly more 
pronounced during treatment and follow-up, the results again did not reach statistical 
significance (Fig. 17). The trend for Il-1 was similar as for TNF, but the IL-10 tendency was 
not as clear.    
 
      
 
Fig. 17 Levels of TNF without (red) and with (green) addition of GTS 21, in the LPS whole blood model. N=12 
and n= 8. 
5.3.2 HRV 
5.3.2.1 HRV in healthy control 
Calculation of HRV variables in a healthy volunteer from ECG recording simultaneous with 
10 minutes of VNS treatment, using the Minimally invasive oscillating device, showed an 
increase of time domain variables SDNN (47.7 - 61.0 ms), RMSSD (34 - 41.5 ms) as well as 
frequency domain variables LF (559 - 1749 ms2 and HF (255 - 382 ms2) suggesting an 
influence on vagal tone (Fig. 18 a,b)  
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 Fig. 18 a) 
  
Fig. 18 b)
 
Fig.18 HRV before (a) and after (b) treatment in a healthy volunteer, top and bottom results respectively. Time 
domain RMSSD and SDNN are increased after 10 minutes treatment with as well as frequency domain LF and 
HF (b). 
5.3.2.2 HRV in hemodialysis patients 
Three patients had a cardiac pacemaker or an implantable cardioverter-defibrillator (ICD) and 
were thus not analyzed for HRV indices. In none of the remaining 9 patients did HRV 
analysis show any significant changes during the study or follow-up.   
 
Outside of the protocol 3 out of 4 patients with insulin dependent diabetes mellitus reported a 
lowering of insulin-doses with about 25% during the study. The fourth patient had only a 
small dose (4 E) long-acting insulin at night. Approximately 3 months after finishing the 
study patients had resumed their original insulin dosing. 
5.4 STUDY IV – PROGNOSTIC POTENTIAL OF HEART RATE AND HEART 
RATE VARIABILITY FOR MONITORING THE CHOLINERGIC ANTI-
INFLAMMATORY PATHWAY 
5.4.1 Correlation of HRV and inflammatory cytokines 
CRP, IL-6, TNF, and E-Selectin had a significantly positive correlation with HR and between 
each other. There was a negative correlation between SDNN and IL-1, IL-6, and E-selectin. 
SD2 was also negatively correlated to E-Selectin. After controlling for confounding factors 
(age, gender, beta-blocker, BMI), the correlations remained significant at p=0.05.  
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5.4.2 Multiple regressions using least mean squares 
Level 7, which included mean HR, SDNN, SD 2, age, gender, BMI, and betablocker resulted 
in the highest correlation coefficient and coefficient of determination for inflammatory 
markers. Level 7 showed the highest predictive power for CRP while TNF showed the least 
correlation with multiple regression (Fig. 19). 
5.4.3 Between group comparisons 
In comparison between groups (CRP <5 and CRP ≥5 µg/ml) regarding HR and HRV indices 
calculated from 5-360 minutes epochs, a positive correlation was observed for CRP ≥5 µg/ml 
and HR. SDNN was negatively related to CRP and hence patients with higher CRP levels had 
lower SDNN. However, this difference was not significant for shorter epochs i.e., 5-60 
minutes, although the trend of lower SDNN for CRP ≥5 µg/ml levels was consistent. 
SDANN was also significantly lower for CRP ≥5 µg/ml but only in 5-minute epochs. 
Frequency domain measurements i.e. HF, LF, and LF/HF seemed to be less reliable and were 
occasionally lower or higher between groups. SD2, which is a non-linear long-term 
measurement based on the Poincaré plot, seemed to be consistently lower, occasionally 
significant for the group with higher CRP levels. Figure 19 illustrates that the 7th level 
(including all parameters) that showed the highest specificity. 
 
 
 
 
 
 
 
 
Fig. 19 ROC analysis for  mean 
RR interval, Ln SDNN, Ln 
SD2, BMI, age and linear 
regression in group with CRP 
>5 µg/mL. A combination of 
personal characteristics and 
HRV indices improves the 
specificity for predicting CRP 
≥ 5 µg/mL. Level  7 result in a 
sensitivity of 83.3% for 
predicting cases with CRP ≥5 
µg/mL however, with a 
specificity of 30.7%.   
 
6 DISCUSSION 
The Cholinergic Anti-inflammatory Pathway is a neuro-immune circuit that safeguards the 
homeostatic balance of inflammatory activity in response to injury, pathogens, and tissue 
ischemia. The afferent portion of the parasympathetic vagus nerve deliver the bulk of sensory 
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information from the thoracic cavity and subdiaphragmatic organs and tissues. The motor or 
the efferent arm of this so-called inflammatory reflex, subsequently responds to and regulates 
the inflammatory response. Several pre-clinical studies have established how this important 
link between the nervous system and the immune system communicates and interacts (26, 33, 
135, 178, 179).  
The recent understanding that inflammation and excessive sympathetic activity can be a 
significant contributor to, or even be causing, non-communicable chronic diseases that 
represent the greater part of the global burden of disease (CVD, stroke, cancer, and 
pulmonary disease), has placed neuro-immunological science and the novel concept of 
bioelectric medicine in the spotlight.  
Chronic inflammation is highly associated with CDK, ESRD and hypertension and is linked 
to a significant increased morbidity and mortality rate (13, 87, 180, 181). 
In this thesis we have studied the CAP and autonomic dysfunction in patients with ESRD, 
and in patients with resistant hypertension treated with RDN. Our main findings are that 
ESRD patients seem to have a functional CAP, with regard to LPS-stimulated cytokine 
release in a whole blood model, and that RND treatment has an immediate impact on CAP 
potentially by influencing CAP bur not with long-lasting effects (176, 177). Furthermore, we 
gained new insights in the possible use of VNS in dialysis as well as the optimal duration of 
HRV measurement and potential correlates with inflammatory cytokines. 
Study I 
 
The finding in study I, with regard to elevated baseline levels of pro-inflammatory cytokines 
in dialysis patients, corroborates findings from previous studies and reflect an underlying 
status of chronic inflammation (87, 91, 92, 98, 99, 176, 180-183). A negative correlation 
between kidney function, expressed as GFR, and inflammatory cytokines and markers (IL-1, 
IL-6, TNF, CRP, and fibrinogen) is well established, but may in part be a retention 
phenomenon due to a decreased clearance of these substances (96, 181). However, elevated 
circulating pro-inflammatory cytokines levels have repeatedly been associated with 
atherosclerosis, CVD, and increased mortality (10, 87, 89, 90, 97, 98). Contributory factors, 
besides inflammation per se, are compromised immune responses due to uremia and an 
impaired performance of neutrophils and lymphocytes. Factors that, all in all, contribute to an 
increased susceptibility and an amplified risk of infections (87, 184-188).  
The LPS-whole blood model has previously been used in studies of RA patients (176, 189). 
We could however note that the dialysis patients diverged from the RA patients by having a 
much more pronounced inflammatory response to LPS in the whole blood model (176, 189, 
190). The reason for this may be that the RA patients were treated with anti-inflammatory 
drugs, which was not the case with the dialysis patients, or that there is a possible intrinsic 
difference between RA and CKD regarding mounting an inflammatory response. However, 
in both groups, where there was a distinct autonomic dysfunction, the pattern of response to 
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the cholinergic agonist was similar, suggesting a functional CAP irrespective of underlying 
disease.  
Study II 
In this study we found a significant decrease in baseline TNF levels one day after RDN, but 
not in the disease controls. We also found strong and significant changes for all 3 cytokines 
(TNF, IL-1b, and IL-10) in the ex vivo LPS stimulated whole blood model, implying that 
cytokine modulation is an instantaneous event after RDN. Yet none of these changes 
remained after 3 and 6 months. This is the first study that has examined anti-inflammatory 
effects longitudinally in the short-, medium, - and long-term after RDN. However, Zaldivia et 
al. demonstrated that RDN reduces cytokine markers, monocyte activation, and monocyte-
platelet aggregate formation at 3 and 6 months follow up (191). Our results and the ones by 
Zaldivia, the latter including a larger number of patients, however, indicate that the effect 
may not be long-lasting or possibly weaker with time. This is of relevance, not only due to 
the renewed interest in RDN as a therapy for resistant hypertension, but also for other 
potential long-term effects. Furthermore, there is in our study no evidence showing, that 
interventions altering sympathetic activity through RDN and thereby potentially changing the 
balance in the autonomic system, can modulate HRV. Nevertheless, this probably should be 
addressed in future studies with larger cohorts. The same may be suggested for inflammation 
and PlGF, the latter being a possible marker of a potentially modifiable neuro-immunological 
pathway in the spleen that may contribute to hypertension (109). 
Interestingly, the cholinergic analogue GTS-21, strengthened the magnitude of TNF 
suppression compared to RDN alone, suggesting a possible mechanistic pathway and 
potential for an additional anti-inflammatory effect in resistant hypertension.  
A role for monocytes in hypertension was investigated in a genetic mouse model of LysM+ 
monocytes depletion leading to a blunted angiotensin-II–induced hypertension. By adoptive 
transfer of proinflammatory monocytes the BP elevation was reestablished, which may serve 
as evidence of the importance of monocytes in hypertension in this model (118). 
A role for α7nAChR in hypertension has been deduced from a model of α7nAChR deficient 
mice exposed to hypertension, where increased end organ damage and higher pro-
inflammatory cytokine levels in serum was found. Chronic administration of PNU-282987, a 
selective α7nAChR agonist, reduced tissue levels of TNF, IL-1, and IL-6 and likewise 
decreased end organ damage in spontaneously hypertensive mice, highlighting the 
therapeutic potential of α7nAChR agonists for reducing hypertension-associated morbidity 
(192).  
Taking everything into account, these findings suggest that repeated or long-term use or 
stimulation of CAP or α7nAChR agonists may be interesting to explore for future therapeutic 
interventions in hypertension. 
Study III 
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Recent human studies, based on previous animal studies, have shown that electrical or 
electromagnetic energy via cervical implants stimulating the vagus nerve may be beneficial 
for patients with inflammatory diseases such as RA and IBD (151, 153, 154, 193, 194). 
Furthermore, in addition to DAS28-CRP, a disease score used in RA, the LPS induced 
inflammation whole blood model, as well as and other inflammatory markers, have been used 
as outcome parameters in studies of VNS in RA (190). 
Chronic inflammation is a typical finding in CKD and in dialysis patients and is linked to 
CVD and all-cause mortality, not only in adult but also in pediatric CKD patients (195). 
However, few trials have been conducted to address this medical conundrum. This is mainly 
because CKD and dialysis patients are a complicated patient group for inclusion in clinical 
studies. A high number of co-morbidities as well as an excessively high susceptibility for 
infections in addition to expected, as well as unexpected, complications such as dialysis 
access problems, have been perceived as impediments (196).  
In this study we used a minimally invasive VNS device rather than an implantable device to 
treat 12 hemodialysis patients before each dialysis session for 4 weeks. The baseline levels of 
CRP and cytokines did not change significantly during this small pilot study, although 
visually there was a trend towards a decreased CRP, TNF, and IL-1 as well as augmented IL-
10. In the LPS induced whole blood model we saw a small trend of TNF and IL-1 reduction 
and IL-10 increase during intervention. In the presence of the cholinergic analogue GTS 21 
there was an additional 50 % reduction of cytokine (TNF) levels. 
We used an equipment that generated vibrations in the left nostril. It may be questioned 
whether vibrations per se are adequate for an afferent vagus nerve signal to be initiated. 
Nevertheless, in a study by Addorisio et al. a “vibrotactile” device was utilized to propagate 
vibrations to the cymba choncha of the outer ear. Both healthy subjects and patients were 
given treatment which resulted in decreased levels of circulating cytokines in healthy subjects 
and lower TNF and disease activity and in patients (164). As the vagus nerve has sensory 
fibers in the pharynx mucosa it is therefore reasonable to assume that the vibrations from the 
VNS equipment we used could have a similar effect (197).  
Although our study did not lead to significant changes in inflammatory markers it may still 
serve as a first step to potentially utilize VNS in this patient group. The enhanced reduction of 
cytokine levels, after adding GTS-21 in the whole blood model, suggests that there may be a 
further potential for cholinergic modulation in patients. Prolonged treatment time at each 
session or a longer protocolized treatment period could be the target for a new and larger trial, 
especially if novel non-invasive devices are proven effective. 
As the spleen is essential for CAP activation recent studies have investigated local 
modulation of splenic activity. In studies by Giglotti et al. a modified ultrasound regimen to 
the spleen was demonstrated in animal models of acute kidney disease and that ultrasound 
may have a protective effect on AKI in sepsis (198). It was also confirmed that the beneficial 
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effect was dependent on α7nAChR on immune cells and not α7nAChR in the parenchyma 
(199). 
Yet another aspect of VNS treatment was elucidated in an experimental intestine 
inflammation model. An implanted VNS electrode was attached to the abdominal part of the 
vagus nerve and stimulation resulted in lower CRP, normal stool, and improved histology. 
VNS did not alter HRV parameters in this study but HR declined during the VNS procedure 
(200). 
In another potential application for kidney patients, Hoeger et al., have interestingly shown 
that vagal stimulation in brain dead donor rats had the ability to decrease chronic allograft 
nephropathy in recipients. This would be an example of CAP contributing to adoptive 
transfer of immune cell and thereby protection against trauma caused by surgery as well as 
inflammation due to rejection (201). 
A very intriguing finding was noted outside the protocol. Three out of four patients with 
diabetes (both T1DM and T2DM) could reduce their insulin doses with 25 % during the 
study. The fourth patient had only a small dose (4 E) long-acting insulin at night. This is in 
line with the results in the study by Hanes et al., in which galantamine was given to patients 
with metabolic syndrome (165). Galantamine treatment for 12 weeks was shown to 
ameliorate inflammation as well as lowering plasma insulin and insulin resistance as 
compared to placebo. These results suggest that the association between inflammation and 
insulin resistance is a potential treatment target. 
 
Other examples of effects observed outside the protocol was better sleep among several of the 
participants. This was manifested by a reduction of the need of sleeping medication. 
Furthermore, several subjects reported an improvement in general mood as well as alertness. 
We cannot however exclude that these effects could be secondary to the attention given to 
patients during the study and the VNS treatment. During the VNS study we utilized 
questionnaires such as SF 36 and EQ5D, but unfortunately these do not include detailed 
questions to describe more subjective experiences and mood changes. These questionnaires 
are more directed toward physical status and activities in daily life and may have been to 
blunt to capture these items as well as cognitive function. For future VNS studies these 
quality of life items, as well as other Patient-Reported Outcome Measures (PROM) and 
Patient-Reported Experience Measures (PREM). may be important to assess. 
 
Study IV 
The significant correlation between HR and HRV and pro-inflammatory cytokines in this 
study are consistent with previous findings (62, 202-204). In addition, the between group 
comparisons indicate that patients with higher CRP levels (CRP ≥5 µg/mL) have a higher HR 
independent of the number of averaged heart beats and hence length of ECG recording. In 
contrast, SDNN showed a significant difference associated with longer recordings. In this 
study, we could not replicate previously reported significant correlations between frequency 
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domain variables and pro-inflammatory markers except for E-Selectin (62, 205, 206). 
However, these previous studies were performed on healthy adults and with different 
circumstances of ECG-recordings; 10 minutes sitting (206), 24 hour Holter ECG (205), and 
11 minutes sitting (62).  
Malik et al. have described that LF and HF in combination with HR might be used to estimate 
basal vagal tone (207). Resting HR in healthy subjects, as a measure of autonomic balance, 
was compared with individuals at risk of RA and with RA patients. Autonomic dysfunction 
was not found in healthy subjects but in individuals at risk of RA. This was was confirmed in 
an independent cohort, where elevated resting HR was associated with arthritis development 
over time (152). A lower HR in combination with high HRV (SDNN) could be interpreted as 
higher vagal tone in patients with lower CRP. Indeed, high HR and low HRV are signs of low 
vagal tone. The prognostic value of heart rate can be observed from correlations, the 
equivalence of the created 7-level model in this study, and from the ROC analysis. It can be 
hypothesized from the 7-level model that using personal characteristics in addition to HRV 
will improve the prognostic value of CRP. Moreover, Houston et al. suggest that HR and 
HRV alone have the potential to be used as a tool to identify patients who may benefit from 
VNS (63). HR and HRV has been used in several studies to reflect the degree of neural 
modulation obtained from VNS (208-211) or pharmacological stimulation (212). Analysis of 
HRV collected by emerging wearable technologies e.g. smart watches would make it possible 
to study lager cohorts and detect early alterations in HRV. Combining HRV data with 
personal characteristics in longitudinal studies may potentially uncover lifestyle risk factors. 
Thus, HRV may potentially be used in a broader context of “personalized health”. 
 
Limitations 
Study I 
The limitation of this study was the relatively small sample size of both patients and controls, 
and moreover that patients and controls were sampled only once. Nevertheless, in a study of 
RA patients of similar design, patients came for 1-8 visits. There were neither significant 
differences in whole blood assay results nor HRV findings at repeated visits suggesting that 
the phenotype in the individual patient is quite similar(189). Another limitation is that ECG-
recordings for HRV were not performed in all patients and not at the same time as blood 
sampling, the latter for practical reasons. All healthy controls were monitored for HRV, but 
similarly as for patients, neither of them at the same occasion as blood draws. Another issue 
was that the control population was significantly younger compared to dialysis patients, 
which could be important as HRV is known to decrease with age (59, 213). 
Lastly, it can also be claimed that the ex vivo whole blood model with GTS-21 does not fully 
represent the in vivo biology. Extensive experience with this model still indicates that the 
cells producing TNF are monocytes responsive to 7nAChR mediated signaling (190). 
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Furthermore, GTS-21 has been proven effective as an immunomodulatory compound by 
attenuating proinflammatory cytokine levels and improving survival in sepsis models (63, 
143). 
Study II 
The limitations of study II were several. The use of RDN was interrupted following the 
neutral results of SYMPLICITY HTN-3 trial, which limited the number of included patients. 
Moreover, the control group was not a sham RDN group although they underwent an 
invasive procedure involving larger arteries. Furthermore, only office blood pressure was 
measured at baseline and follow-up at 6 months. Ambulatory blood pressure monitoring is 
commonly used in clinical trials of RDN and is considered to more adequately capture the 
variability of estimates of blood pressure changes (214). Finally, we considered whether the 
use of pre- and periprocedural administration of i.v. diazepam and analgesia could have had 
some anti-inflammatory effect per se in the RDN patients, but the true influence of this may 
been difficult to assess (215).  
Study III 
In this pilot study we recruited only 12 patients which may have influenced the study 
outcome to some extent. During follow-up four out of twelve patients suffered from events 
associated with inflammation, which added to the difficulties in interpreting the results. 
Another important factor was a quite wide range of baseline levels of inflammatory markers. 
The VNS device used in the study had not previously been applied in a study focusing on 
inflammatory response, and thus may not have been effective enough. However, a more 
likely explanation for the minor results is probably the fact that we only had one device and 
could not deliver the treatment daily which would have been preferable. Previous clinical 
studies, investigating VNS in inflammatory conditions, have had used protocols with 
implantable devices allowing daily and, in some cases, repeated daily sessions of stimulation. 
An implantable VNS device in dialysis patients could however, in our view, have been 
problematic in a patient population with a ubiquitous risk of infectious complications. For 
future studies, we aspire to more frequent and prolonged VNS treatment, but preferably using 
non-invasive easy to administer devices.  
Study IV 
This was the study with the largest number of patients. Still there were some shortcomings. In 
this study an absolute threshold of a CRP level of 5 µg/mL was used for comparison between 
groups. In healthy individuals a CRP threshold of 3 µg/mL is suggested to be the range for 
intermediate to high risk factors for developing coronary heart disease (216, 217). However, a 
threshold of 3 µg/mL in this study would probably not have changed the results significantly, 
regarding correlation with HRV, but may have had some influence on the threshold level 
where this correlation is valid. 
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Circadian variation of HRV and HR and altered HRV and HR during apnea, has been 
reported (218). However, in our analysis the apnea episodes were not excluded but 
considered as strong short-term confounding factors. The absence of additional anti-
inflammatory cytokines in the HeartBEAT database was a limitation that should be 
considered in further studies. 
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7 CONCLUSION 
Study I 
We have here shown that immune cells from dialysis patients can mount an anti-
inflammatory response after cholinergic stimulation. These are novel findings in this patient 
population afflicted with autonomic dysfunction coupled with an underlying dysregulated 
cytokine response. In the evolving therapeutic field of neuroimmunomodulation and 
bioelectronic medicine our data is a piece of the puzzle, which may facilitate future trials 
using cholinergic modalities in the CKD population. 
Study II 
Hypertension contributes significantly to cardiovascular morbidity and mortality rates 
worldwide. Catheter-based radiofrequency ablation has been used as an invasive add-on 
treatment for resistant hypertension in clinical trials. We have shown that modulation of renal 
sympathetic nerve activity trough RDN has an instantaneous effect in a model of LPS-
stimulated cytokine release, but that is not sustained over time.  When adding a cholinergic 
analogue to LPS-stimulated samples, a more marked effect on cytokine levels was recorded. 
This may indicate that repeated or long-term stimulation of CAP, rather than a single RDN 
treatment, could potentially be more effective in reducing inflammation. The axis involving 
sympathetic-parasympathetic nerves, PlGF, and inflammatory cells as a potential target for 
therapeutic intervention by neuro-modulating devices in hypertension merits further research. 
Study III 
Although the reduction of inflammatory markers did not reach statistical significance in this 
short-term VNS pilot study, we suggest that our study could serve as a foundation to 
potentially utilizing VNS in this patient group. One may speculate that prolonged daily 
treatment time at each session or a longer protocolized treatment period could have improved 
the outcome as was the case in recent clinical trials. Studies using cervical vagus implants 
have demonstrated significant inhibition of cytokine production and disease activity in 
patients with RA after 4 to 8 weeks with daily VNS and 6 months of daily VNS in Crohn´s 
disease. However, a non-invasive device for self-use would be preferable to reduce the 
burden of chronic inflammation in CKD patients prior to and on dialysis. 
Study IV 
HRV is the most common tool to measure the activity of sympathetic and parasympathetic 
nerve activity. HRV is known to correlate with inflammatory markers which was shown also 
in this study. The selection of markers, however, was limited. Longer ECG recordings (360 
min) was shown to reflect SDNN the best. For other variables it seems that shorter recording 
are as reliable as longer ones. Regarding HRV the optimal duration of HRV measurements 
and potential correlates with inflammatory cytokines should be studied further in clinical 
trials. 
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8 FUTURE PERSPECTIVES 
The concept of the immune system and the nervous system as being two different entities 
without any interaction is no longer true. There is uncontested evidence of communication 
and collaboration, and furthermore that the immune system is a prerequisite for the function 
of the nervous system and vice-versa.  
Recent and ongoing research further expands this perspective and future therapeutic 
possibilities. Both CKD and hypertension are associated with chronic inflammation as are 
many other major non-communicable diseases. HRV analysis and the development of other 
physiological assessment methods may become more useful in clinical practice in the future. 
Muscular sympathetic nerve activity has been shown to be elevated in patients with EHT both 
when untreated and during treatment with antihypertensive drugs. (106). This may suggest a 
previously unrecognized masked sympathetic activation and baroreflex dysfunction in true 
resistant hypertension. Newer non-drug related devices for treatment of hypertension are 
under development (219, 220). In the future it may be important to determine which patients 
could benefit from this kind of intervention (221, 222). The potential use of tools that may 
more effectively address both hypertension and inflammation is of considerable interest. 
There are also ongoing efforts to find biological markers for HRV as a substitute for HRV. A 
recent study has tried to evaluate serum cholinesterase activity (CAA) in healthy subjects to 
estimate autonomic balance. CAA at rest was shown to predict some of the HRV parameters 
changes during exercise in a sex-dependent manner. Even more interesting was that a 
correlation was found between higher CAA and detectable high sensitive Troponin T 
(hsTnT) in women, in which hsTnT is normally not detected without known cardiovascular 
disease (223). Whether this can be used as an early risk marker for cardiovascular disease 
warrants further studies. 
Increased morbidity and mortality in CKD are continuous major problems. Some of the 
underlying causes and disease mechanisms are well known. These factors are still a challenge 
to address on a population basis, but also in the individual patient. Better dialysis treatment 
and better tools to reduce chronic inflammation is certainly of outmost importance, whereas 
pre-dialysis patients need other types of interventions which among other components should 
also focus on inflammation. CKD with or without dialysis and associated co-morbidities 
contribute to years of decreased quality of life for patients. Its share of both national and 
international health economy is furthermore substantial. Interesting new interventional 
studies in the field of CAP in AKI, and CKD, which also involves our preliminary results 
from the VNS in dialysis study, may in the future be of great and substantial benefit in AKI, 
AKD, CKD, and associated inflammatory conditions. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Bakgrund: Det icke viljestyrda, autonoma nervsystemet, består av sympatikus som 
förbereder kroppen för kamp och flykt och parasympatikus som är mer aktivt i vila. Obalans 
mellan sympatisk och parasympatisk aktivitet, autonom dysfunktion, kan mätas med EKG. 
Utifrån EKG beräknas variationer i tid mellan hjärtslagen – hjärtslagsvariabilitet (HRV).  
Autonom dysfunktion och kronisk inflammation ses vid en rad olika sjukdomar, till exempel 
reumatism (RA), inflammatorisk tarmsjukdom (IBD), diabetes, högt blodtryck och kronisk 
njursvikt. Både autonom dysfunktion och inflammation är förknippade med ökad sjuklighet 
och dödlighet i framförallt hjärt- och kärlsjukdom hos dessa patienter.  
Den kolinergiska anti-inflammatoriska effektorvägen (CAP) är en nervkrets där vagusnerven 
reglerar det medfödda immunförsvaret. Vid tex vävnadsskada, syrebrist eller bakterieangrepp 
bildar immunförsvaret ämnen (cytokiner) som en del av den inflammatoriska reaktionen. 
Vagusnerven reagerar på detta och sänder signaler till förlängda märgen som reflexmässigt 
skickar signaler till mjälten. I mjälten finns celler som tillverkar en substans, acetylkolin, som 
när den når det inflammerade området dämpar immunförsvarets aktivitet. På så sätt kan 
kroppen kontrollera och reglera den inflammatoriska aktiviteten och förhindra att den blir för 
hög så att kroppen tar skada istället för att läka. 
I små studier på patienter med RA och IBD har man stimulerat vagusnerven (VNS) med en 
pacemakerliknande anordning och sett positiva effekter.  
Syftet med studierna i denna avhandling var att undersöka om dialyspatienter har 
immunceller som reagerar på stimulering av vagusnerven och om det skulle kunna påverka 
nivåerna av cytokiner i blodet. Vi ville också undersöka patienter som genomgått renal 
denervering (RDN) (”bränning” av sympatiska nerver i njurens artärer) pga. svårbehandlat 
högt blodtryck. Vår frågeställning var om de skulle få minskade nivåer av cytokiner som 
resultat av minskad sympatisk nervaktivitet. Slutligen var syftet med avhandlingen också att 
utforska förhållandet mellan cytokiner och olika långa mätningar av hjärtslagsvariabilitet. 
Material och metoder: I våra studier har vi använt blodprov som stimulerats med LPS (del 
av bakterievägg) för att åstadkomma en kraftig inflammatorisk reaktion. När cytokinnivåerna 
stigit har vi satt till ett ämne (GTS 21) som liknar det som mjälten utsöndrar och mätt om 
cytokinnivåerna, dvs inflammationen minskade. I studie I lämnade 20 dialyspatienter och 12 
friska kontroller blodprov. I studie II tog vi blodprov på 10 patienter som behandlades med 
RDN och följde dem i sex månader. I studie III lät vi 12 dialyspatienter genomgå VNS före 
varje dialys i fyra veckor (12 behandlingar). Stimuleringen gjordes med en liten vibrerande 
ballong i vänster näsborre i 10 minuter. Blodprov togs vid flera tillfällen under och efter 
behandlingsperioden. I alla studierna tog vi EKG på försökspersonerna och beräknade HRV. 
I studie IV använde vi en databas med nattliga EKG-mätningar för att titta på samband 
mellan hjärtslagsvariabilitet och cytokiner.  
Resultat: I studie I såg vi att dialyspatienter producerar cytokiner i högre utsträckning än 
friska men när vi tillsatte GTS 21 i proverna sjönk cytokinnivåerna lika mycket i bägge 
grupperna. I studie II visade blodproverna att RDN-patienter hade lägre cytokinnivåer dagen 
efter RDN men efter 6 månader hade de stigit till utgångsnivån igen. I studie III kunde vi inte 
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se klart minskade cytokinnivåer under eller efter VNS-behandling även om det fanns en 
trend. Studie IV visade att 360 minuters EKG registrering var mest rättvisande avseende vissa 
HRV-mått och att det fanns ett visst samband med cytokinnivåer.  
Slutsats: Dialyspatienter har en fungerande CAP och VNS skulle kunna vara en möjlig 
behandling för att minska inflammation och potentiellt risken för hjärt-och kärlsjukdom. 
Troligen behövs dock intensivare behandling med dagliga eller längre behandlingar. RDN 
minskar cytokinnivåerna på kort sikt men är i sin nuvarande form inget alternativ som 
antiinflammatorisk behandling. I framtiden kan långtidsmätningar av HVR möjligen 
användas i kliniska studier på inflammation som ett mått på behandlingseffekt.
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